title: [The advances of the drug therapy for pulmonary fibrosis].
abstract: Idiopathic pulmonary fibrosis is a relentlessly progressive and typically fatal interstitial lung disease that harms human life severely. Half of patients diagnosed as idiopathic pulmonary fibrosis live no more than three years. No therapy has been clearly shown to prolong survival. Multiple new targets for pulmonary fibrosis have been indicated based on the researches that uncover the molecular and cellular mechanisms for fibrogenic diseases. In this review, we will summarize the clinical treatment for pulmonary fibrogenic diseases and new drugs with clinic trail, and then review focally the prospects of new drugs for pulmonary fibrogenic diseases that target alveolar epithelial cells or myofibroblast, inhibit the angiogenesis, regulate the balance of TH1/TH2 cytokines or block oxide stress.
authors.affiliation: Institute of Meteria Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China.
authors.forename: Bing
authors.initials: B
authors.lastname: Cui
authors.forename: Zhuo-Wei
authors.initials: ZW
authors.lastname: Hu
mesh_terms: D015195:Drug Design; D004847:Epithelial Cells; D006801:Humans; D032446:Myoblasts; D009389:Neovascularization, Pathologic; D018384:Oxidative Stress; D011650:Pulmonary Alveoli / Q000166:cytology; D011658:Pulmonary Fibrosis / Q000188:drug therapy*; D058408:Th1-Th2 Balance